« Return to News | R&D Trends

Evotec, IR Pharma partner for respiratory disease drug discovery

Friday, February 17, 2012 01:41 PM

Evotec and IR Pharma have formed an exclusive strategic alliance to provide integrated drug discovery solutions to pharmaceutical and biotech companies in the field of respiratory diseases.

The alliance expands Evotec's drug discovery platform into the area of respiratory diseases through IR Pharma's expertise in in vitro and in vivo respiratory pharmacology. Evotec can now offer fully-integrated respiratory- and inflammation-focused drug discovery programs to its partners, from target to nomination of pre-clinical development candidates.

"IR Pharma has outstanding expertise in the respiratory disease area including disease relevant in vivo models, and coupled with our world-leading discovery engine and commercial reach, we are sure we can bring outstanding value to existing and future partners and collaborators in these demanding disease areas,” said Dr. Mario Polywka, COO at Evotec.

Maria Belvisi, director at IR Pharma, added, "We have a range of highly validated models, focusing on asthma, cough and Chronic Obstructive Pulmonary Disease (COPD), which ideally complement Evotec's platform, thus enabling a fully integrated approach to drug discovery in this challenging area."

No financial details were disclosed.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.